Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro

References

• Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006; 108:618–21; PMID:16569772; http://dx.doi.org/10.1182/blood-2005-10-4184
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98:210–6; PMID:11418482; http://dx.doi.org/10.1182/blood.V98.1.210
   PubMed Web of Science ®Google Scholar
• Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ, Neeson P, Ritchie DS. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood 2011; 117:1605–13; PMID:20978269; http://dx.doi.org/10.1182/blood-2010-04-278432
   PubMed Web of Science ®Google Scholar
• Song W, van der Vliet HJ, Tai YT, Prabhala R, Wang R, Podar K, Catley L, Shammas MA, Anderson KC, Balk SP et al. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res 2008; 14:6955–62; PMID:18980990; http://dx.doi.org/10.1158/1078-0432.CCR-07-5290
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58:1033–45; PMID:19009291; http://dx.doi.org/10.1007/s00262-008-0620-4
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004; 103:1787–90; PMID:14512311; http://dx.doi.org/10.1182/blood-2003-02-0361
   PubMed Web of Science ®Google Scholar
• Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 2013; 62:39–49; PMID:22733396; http://dx.doi.org/10.1007/s00262-012-1308-3
   PubMed Web of Science ®Google Scholar
• De Keersmaecker B, Fostier K, Corthals J, Wilgenhof S, Heirman C, Aerts JL, Thielemans K, Schots R. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation. Cancer Immunol Immunother 2014; 63:1023–36; PMID:24947180; http://dx.doi.org/10.1007/s00262-014-1571-6
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta A et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol 2014 Mar; 164(6):811-21; PMID:24328678; http://dx.doi.org/10.1111/bjh.12708
   Google Scholar
• Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26:2326–35; PMID:22552008; http://dx.doi.org/10.1038/leu.2012.119
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118:4771–9; PMID:21860026; http://dx.doi.org/10.1182/blood-2011-05-356063
   PubMed Web of Science ®Google Scholar
• Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 2015; 125:4042–51; PMID:25869284; http://dx.doi.org/10.1182/blood-2014-11-611426
   PubMed Web of Science ®Google Scholar
• Ozaki S, Harada T, Fujii S, Nakamura S, Miki H, Nakano A, Kagawa K, Takeuchi K, Abe M, Matsumoto T. Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma. Int J Hematol 2011; 93:257–9; PMID:21279817; http://dx.doi.org/10.1007/s12185-011-0775-1
   PubMed Web of Science ®Google Scholar
• Busch A, Zeh D, Janzen V, Mugge LO, Wolf D, Fingerhut L, Hahn-Ast C, Maurer O, Brossart P, von Lilienfeld-Toal M. Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Exp Immunol 2014; 177:439–53; PMID:24712857; http://dx.doi.org/10.1111/cei.12343
   PubMed Web of Science ®Google Scholar
• Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, Cornelissen JJ, Janssen JJ, Huisman C, Cornelisse PB et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011; 118:2413–9; PMID:21690556; http://dx.doi.org/10.1182/blood-2011-04-348292
   PubMed Web of Science ®Google Scholar
• Wolschke C, Stubig T, Hegenbart U, Schonland S, Heinzelmann M, Hildebrandt Y, Ayuk F, Atanackovic D, Dreger P, Zander A et al. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. Experimental Hemato 2013; 41:134-42 e3; PMID:23085463; http://dx.doi.org/10.1016/j.exphem.2012.10.004
   PubMed Web of Science ®Google Scholar
• Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D et al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014; 20:1183–9; PMID:24769014; http://dx.doi.org/10.1016/j.bbmt.2014.04.014
   PubMed Web of Science ®Google Scholar
• Govindaraj C, Madondo M, Kong YY, Tan P, Wei A, Plebanski M. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. Am J Hematol 2014 Aug; 89(8):795-802; PMID:24757092; http://dx.doi.org/10.1002/ajh.23746
   Google Scholar
• Clave E, Douay C, Coman T, Busson M, Bompoint C, Moins-Teisserenc H, Glauzy S, Carmagnat M, Gorin NC, Toubert A et al. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis. Leuk Lymphoma 2013 Aug; 55(8):1788-95; PMID:24237448; http://dx.doi.org/10.3109/10428194.2013.865182
   Google Scholar
• Harada T, Ozaki S, Oda A, Tsuji D, Ikegame A, Iwasa M, Udaka K, Fujii S, Nakamura S, Miki H et al. Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors. PLoS One 2013 Dec 26; 8(12):e83905; PMID:24386306; http://dx.doi.org/10.1371/journal.pone.0083905
   Google Scholar
• Ozaki S, Kosaka M, Harada M, Nishitani H, Odomi M, Matsumoto T. Radioimmunodetection of human myeloma xenografts with a monoclonal antibody directed against a plasma cell specific antigen, HM1.24. Cancer 1998; 82:2184–90; PMID:9610698; http://dx.doi.org/10.1002/(SICI)1097-0142(19980601)82:11%3c2184::AID-CNCR13%3e3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood 1997; 90:3179–86; PMID:9376601
   PubMed Web of Science ®Google Scholar
• Neuber B, Herth I, Tolliver C, Schoenland S, Hegenbart U, Hose D, Witzens-Harig M, Ho AD, Goldschmidt H, Klein B et al. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma. J Immunol 2011; 187:1047–56; PMID:21677134; http://dx.doi.org/10.4049/jimmunol.1002460
   PubMed Web of Science ®Google Scholar
• Chan AC, Neeson P, Leeansyah E, Tainton K, Quach H, Prince HM, Harrison SJ, Godfrey DI, Ritchie D, Berzins SP. Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin Exp Immunol 2014; 175:49–58; PMID:24032527; http://dx.doi.org/10.1111/cei.12196
   PubMed Web of Science ®Google Scholar
• Hallett WH, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant 2011; 17:1133–45; PMID:21536144; http://dx.doi.org/10.1016/j.bbmt.2011.03.011
   PubMed Web of Science ®Google Scholar
• Clave E, Douay C, Coman T, Busson M, Bompoint C, Moins-Teisserenc H, Glauzy S, Carmagnat M, Gorin NC, Toubert A et al. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis. Leuk Lymphoma 2014; 55:1788–95; PMID:24237448; http://dx.doi.org/10.3109/10428194.2013.865182
   PubMed Web of Science ®Google Scholar
• Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 2009; 23:605–7; PMID:18784738; http://dx.doi.org/10.1038/leu.2008.247
   PubMed Web of Science ®Google Scholar
• Herth I, Witzens-Harig M, Beckhove P, Hose D, Meissner T, Neuber B, Engelhardt M, Haas J, Neben K, Ho AD et al. Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma. Exp Hematol 2013; 41:231–40; PMID:23142220; http://dx.doi.org/10.1016/j.exphem.2012.10.018
   PubMed Web of Science ®Google Scholar
• Nachbaur D, Kropshofer G, Heitger A, Latzer K, Glassl H, Ludescher C, Nussbaumer W, Niederwieser D. Phenotypic and functional lymphocyte recovery after CD34+-enriched vs. non-T cell-depleted autologous peripheral blood stem cell transplantation. J Hematother Stem Cell Res 2000; 9:727–36; PMID:11091497; http://dx.doi.org/10.1089/15258160050196777
   PubMedGoogle Scholar
• Peggs KS, Verfuerth S, Pizzey A, Khan N, Moss P, Goldstone AH, Yong K, Mackinnon S. Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection. Biol Blood Marrow Transplant 2003; 9:198–205; PMID:12652471; http://dx.doi.org/10.1016/S1083-8791(03)70010-X
   PubMed Web of Science ®Google Scholar
• van der Velden AM, Claessen AM, van Velzen-Blad H, Biesma DH, Rijkers GT. Development of T cell-mediated immunity after autologous stem cell transplantation: prolonged impairment of antigen-stimulated production of gamma-interferon. Bone Marrow Transplant 2007; 40:261–6; PMID:17563737; http://dx.doi.org/10.1038/sj.bmt.1705706
   PubMed Web of Science ®Google Scholar
• Wolniak KL, Goolsby CL, Chen YH, Chenn A, Singhal S, Jayesh Mehta, Peterson LA. Expansion of a clonal CD8+CD57+ large granular lymphocyte population after autologous stem cell transplant in multiple myeloma. Am J Clin Pathol 2013; 139:231–41; PMID:23355208; http://dx.doi.org/10.1309/AJCP1T0JPBLSLAQF
   PubMed Web of Science ®Google Scholar
• Focosi D, Bestagno M, Burrone O, Petrini M. CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol 2010; 87:107–16; PMID:19880576; http://dx.doi.org/10.1189/jlb.0809566
   PubMed Web of Science ®Google Scholar
• Hundemer M, Schmidt S, Condomines M, Lupu A, Hose D, Moos M, Cremer F, Kleist C, Terness P, Belle S et al. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Experimental Hematol 2006; 34:486–96; PMID:16569595; http://dx.doi.org/10.1016/j.exphem.2006.01.008
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102:1115-23; PMID:9753033; http://dx.doi.org/10.1046/j.1365-2141.1998.00930.x
   PubMed Web of Science ®Google Scholar